Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic ...
Genetic tests make up a growing share of total spending on laboratory tests under Medicare Part B, according to a report posted last week by the HHS’ Office of Inspector General. They comprised 43% of ...
Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testingSupports iMDx's ...
When you have a rare disease, managing doctor’s appointments, prescriptions and care plans is difficult enough — figuring out what Medicare will (and won’t) cover often adds another layer of stress.
InvestorsHub on MSN
CareDx shares jump as Medicare finalizes transplant testing coverage policy (CDNA)
Final Medicare policy supports transplant surveillance portfolio CareDx Inc. (NASDAQ:CDNA) shares climbed 20% on Thursday ...
A Jan. 28 report on Medicare spending on lab tests indicated that spending on many types of tests flattened between 2022 and 2024, but spending on genetic tests rose 20% between 2023 and 2024 to $3.6 ...
CareDx (NASDAQ:CDNA) price surged ~18% in premarket trading to ~$35.15 on Thursday after the company announced that Medicare finalized its Local Coverage Determination (LCD) policy for molecular ...
ENTERPRISE, Ala. (WTVY) - Seniors across the country are being targeted by a growing Medicare scam that starts with a simple phone call. Scammers are calling older adults, offering free genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results